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CASE PRESENTATION
A 59-year-old woman was admitted to the hos-
pital because of spontaneous subcutaneous hem-
orrhage and petechial rashes. The patient had
been well until 1 week before she noticed some
skin lesions and spontaneous mucosal bleeding.
She did not take any medication and in her past
medical history she had undergone hysterectomy
because of a documented nonmalignant endome-
trial proliferation 15 years earlier. On admission,
her temperature was 37.2°C and blood pressure
120/80 mmHg. Physical examination showed no
splenomegaly and no other abnormalities except
petechial rashes on extremities. Peripheral blood
smear showed severe thrombocytopenia.
Complete blood count revealed hemoglobin
(Hb) 13.2 g/dL, white blood cell (WBC)
4000/m3 with normal differentiation and platelet
(Plt) 8000/dL (Table 1). Serum protein elec-
trophoresis was normal. Direct and indirect
Coombs’ test was negative. Serologic markers for
infectious disease (including toxoplasmosis,
human immunodeficiency virus [HIV], hepatitis
A, B, and C viruses [HAV, HBV, and HCV], and
Epstein-Barr virus [EBV]) were negative. C3, C4,
and CH50 were normal (29%, 125%, and 94%,
respectively) and antinuclear antibody (ANA)
were negative. Cutaneous tuberculin test was 5
mm. Her chest x-ray and abdominal ultrasonog-
raphy revealed no pathologic findings. A bone
marrow biopsy showed normal cellular matura-
tion and increased megakaryocytes.
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Summary: Idiopathic thrombocytopenic purpura (ITP) is an im-
mune-mediated disorder characterized by accelerated and premature
destruction of platelets by reticuloendothelial system. CD20, a trans-
membrane B-cell-specific antigen, is a potential target for treatment
of certain malignant and nonmalignant plasma cell disorders includ-
ing refractory ITP. Rituximab is a genetically engineered human anti-
CD20 monoclonal antibody, which is approved for the treatment of
low-grade non-Hodgkin’s lymphoma. Recent clinical reports suggest
that rituximab may be useful in treating certain patients with
chronic refractory ITP. A 59-year-old woman with refractory ITP was
placed on rituximab (four weekly doses of 375 mg/m2) and her con-
dition and platelet count were observed for 18 months. There was a
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selection should be done.
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A diagnosis of idiopathic thrombocytopenic
purpura (ITP) was made. She was placed on oral
prednisolone 75 mg/day and her Plt count in-
creased to 360 × 103/m3 by the end of second
week. In the fourth week when she received 50
mg/day of prednisolone, Plt count dropped to
80 × 103/m3. 
Over the next 2 months, because she had
some adverse effects of the corticosteroid (dys-
pepsia and generalized edema), prednisolone
was tapered to 7.5 mg every other day and dana-
zol 400 mg/day was begun. The Plt count was
between 40 × 103 and 80 × 103/m3 and she was
symptom-free.
In the sixth month, again she experienced
spontaneous mucosal bleeding and the Plt count
dropped to 8 × 103/m3. She was admitted to the
hospital and received hydrocortisone 400
mg/day and high-dose intravenous immuno-
globulin (IVIG) 400 mg/kg for 5 days, which
gave a transient increase in Plt count that
dropped again after 2 weeks.
She underwent splenectomy and its pathology
revealed reactive hyperplastic change. On the sec-
ond day after surgery her Plt count was 86 ×
103/m3 but dropped to less than 10 × 103/m3 on
the fourth day. She was placed on high-dose
methylprednisolone 1500 mg/day that gave no
response. After 2 weeks her Plt count was less
than 10 × 103/m3 and she had a bloody secretion
in her drain bag. She received two courses of vin-
cristin 1 mg/week with no increase in Plt count.
A bone marrow biopsy was repeated and spec-
imens reviewed by an expert hematologist were
compatible with ITP and there was no myelodys-
plastic or neoplastic change.
After about 9 months of treatment the patient
was refractory to medications, Plt count was less
than 50 × 103/m3, and her mucosa surfaces had
easy bruising (Fig. 1). Finally we decided to place
the patient on anti-CD20 monoclonal antibody,
rituximab. She received the drug in four weekly
doses of 375 mg/m2 and her Plt count increased
to 188 × 103/m3) in 2 months. About 18 months
after treatment the patient has no complaint, does
not have a Plt count of less than 80 × 103/m3, and
her Plt count has increased gradually.
DISCUSSION
ITP is an immune-mediated disorder charac-
terized by accelerated and premature destruction
of platelets by the reticuloendothelial system (1).
Spontaneous remission is rare in adult patients
but about 50% of cases respond to primary treat-
ments including corticosteroid, IVIG, anti-RhD
immunoglobulin, and splenectomy (2). 
Chronic and refractory patients who fail pri-
mary modalities and experience sustained throm-
bocytopenia are difficult to manage. Treatments
that aim at suppressing the production of au-
toantibodies and inhibiting macrophage-mediat-
ed destruction of opsonized platelets include
danazol, cytotoxic/immunosuppressive chemo-
therapy agents (cyclophosphamide, vincristine,
azathioprine), and the new anti-CD20 mono-
clonal antibody (2,3).
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TABLE 1. Hematological Laboratory Results
Indices (Unit) On Admission After 2 weeks After 21¼2 Years
Hct (%) 38.9 41.8 45.3
Hg (g/dL) 13.2 14.8 15
RBC (m3) 4.59 × 106 5.17 × 106 5.14 × 106
MCV (fL) 85 83 88
MCH (pg) 29 31 29
MCHC (g/dL) 34 36 33
WBC (m3) 4 × 103 13.1 × 103 6.1 × 103
Platelet (m3) 8 × 103 360 × 103 280 × 103
Hct = hematocrit; Hg = hemoglobin; RBC = red blood cell; MCV = mean corpuscular volume; MCH = mean corpuscular
hemoglobin; MCHC = mean corpuscular hemoglobin concentration; WBC = white blood cell.
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CD20, a transmembrane B-cell-specific anti-
gen, is a potential target for treatment of certain
malignant and nonmalignant plasma cell disor-
ders (4). Rituximab is a genetically engineered
human anti-CD20 monoclonal antibody that is
approved for the treatment of low-grade non-
Hodgkin’s lymphoma. Recent clinical reports sug-
gest that rituximab may be useful in treating cer-
tain patients with chronic refractory ITP (3–10). 
Possible mechanisms for rituximab’s activity
are the destruction of autoantibody-producing
plasma cells and the blockade of immune effector
cell-mediated destruction of antibody-coated
platelets (4).
Perotta et al (10) have reported a series of
10 patients with chronic ITP who failed to re-
spond initial treatments and 9 of whom had un-
dergone splenectomy. Patients received ritux-
imab 375 mg/m2 weekly for 4 weeks. Five pa-
tients (50%) had a complete response (CR) (Plt
count > 100 × 103/m3) and one (10%) had a
partial response (PR) (Plt count 50–100 ×
103/m3) and the duration of response was be-
tween 1 and 14 months.
Saleh et al (3) conducted a phase I/II clinical
trial of 13 patients with refractory ITP. Rituximab
was well tolerated with no obvious toxicity. PR
was detected in two patients and lasted for 3 to 6
months and only one patient showed a CR for
more than 6 months and all received full doses.
Stasi et al (6) reported a cohort of 25 chronic ITP
patients. In their study they found 5 patients
with CR, 5 patients with PR, and 3 patients with
a minor response (MR) (Plt count < 50 ×
103/m3, with no need for continuous treatment)
and overall response was 52%, which lasted for
at least 6 months. There are also some anecdotal
case reports of chronic ITP patients treated with
rituximab that show promising results. 
In the current reported case, as shown in Fig.
1, the patient was refractory to all medications
after about 1 year of treatment, but when she re-
ceived rituximab she experienced a CR for more
than 18 months, with minimal side effects of the
treatment. In the follow-up period, in the seventh
month, her Plt count declined to less than 100 ×
103/m3, and there has been no need for any ad-
ditional course of treatment.
In conclusion, we have no clear guidelines for
management of chronic refractory ITP. Rituxi-
mab, as an anti-CD20 monoclonal antibody,
shows some application in this field, but proper
use of this treatment, alone and in combination
with other modalities, needs further study. 
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FIG. 1. Platelet count variation and treatment interventions.
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